KR20240007140A - Psd-95 억제제 및 이의 용도 - Google Patents

Psd-95 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20240007140A
KR20240007140A KR1020237037930A KR20237037930A KR20240007140A KR 20240007140 A KR20240007140 A KR 20240007140A KR 1020237037930 A KR1020237037930 A KR 1020237037930A KR 20237037930 A KR20237037930 A KR 20237037930A KR 20240007140 A KR20240007140 A KR 20240007140A
Authority
KR
South Korea
Prior art keywords
seq
cpp
compound
compound according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237037930A
Other languages
English (en)
Korean (ko)
Inventor
비타 세레이카이테
크리스티안 라인하르트 오토 베크-바틀링
크리스티안 스트롬가드
Original Assignee
유니버시티 오브 코펜하겐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 코펜하겐 filed Critical 유니버시티 오브 코펜하겐
Publication of KR20240007140A publication Critical patent/KR20240007140A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237037930A 2021-05-12 2022-05-12 Psd-95 억제제 및 이의 용도 Pending KR20240007140A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173587 2021-05-12
EP21173587.3 2021-05-12
PCT/EP2022/062893 WO2022238530A1 (en) 2021-05-12 2022-05-12 Psd-95 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20240007140A true KR20240007140A (ko) 2024-01-16

Family

ID=75914418

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037930A Pending KR20240007140A (ko) 2021-05-12 2022-05-12 Psd-95 억제제 및 이의 용도

Country Status (16)

Country Link
US (1) US20240245793A1 (https=)
EP (1) EP4337673B1 (https=)
JP (1) JP2024520234A (https=)
KR (1) KR20240007140A (https=)
CN (1) CN117295755A (https=)
AU (1) AU2022274309A1 (https=)
BR (1) BR112023021410A2 (https=)
CA (1) CA3218073A1 (https=)
ES (1) ES3040762T3 (https=)
IL (1) IL307244A (https=)
MX (1) MX2023013313A (https=)
PL (1) PL4337673T3 (https=)
SA (1) SA523451347B1 (https=)
TW (1) TW202306965A (https=)
WO (1) WO2022238530A1 (https=)
ZA (1) ZA202308712B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
JP7723457B2 (ja) * 2023-07-03 2025-08-14 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽
CN119569824A (zh) * 2023-09-07 2025-03-07 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004003A2 (en) 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
ES2544573T3 (es) 2011-05-13 2015-09-01 Københavns Universitet (University Of Copenhagen) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
WO2020083905A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Also Published As

Publication number Publication date
ZA202308712B (en) 2025-02-26
PL4337673T3 (pl) 2026-01-05
AU2022274309A9 (en) 2024-01-25
US20240245793A1 (en) 2024-07-25
ES3040762T3 (en) 2025-11-04
CN117295755A (zh) 2023-12-26
EP4337673A1 (en) 2024-03-20
JP2024520234A (ja) 2024-05-23
CA3218073A1 (en) 2022-11-17
MX2023013313A (es) 2023-12-04
SA523451347B1 (ar) 2024-08-27
BR112023021410A2 (pt) 2023-12-19
EP4337673B1 (en) 2025-07-09
TW202306965A (zh) 2023-02-16
AU2022274309A1 (en) 2023-09-28
WO2022238530A1 (en) 2022-11-17
EP4337673C0 (en) 2025-07-09
IL307244A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
KR20240007140A (ko) Psd-95 억제제 및 이의 용도
JP6722227B2 (ja) ヘプシジン類似体及びその使用
JP6480865B2 (ja) 新規なα４β７ペプチド二量体拮抗薬
KR102046830B1 (ko) 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
KR100679576B1 (ko) 수용체에 결합하는 펩티드 및 화합물
AU2021399076B2 (en) Polypeptides and uses thereof
JP6633523B2 (ja) Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
WO2014063012A1 (en) Conjugated knottin mini-proteins containing non-natural amino acids
KR20250043599A (ko) α4β7 인테그린 티오에테르 펩티드 길항제
JP2599947B2 (ja) ペプチド化合物
CA3247142A1 (en) CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY
US20170246311A1 (en) Peptides for binding alternatively activated macrophages
CA2937032C (en) Activated neurotensin molecules and the uses thereof
US11357863B2 (en) Peptide conjugates
HK40108323B (en) Psd-95 inhibitors and uses thereof
HK40108323A (en) Psd-95 inhibitors and uses thereof
WO2026058014A1 (en) Peptide conjugates comprising blood brain barrier penetrating oligopeptides for use in therapeutic and diagnostic methods
HK1229227B (en) Fatty acid derivatives of dimeric inhibitors of psd-95

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250409

Comment text: Request for Examination of Application